Business
New Science & Innovation Business Unit to Advance Aurora's Leadership in Biosynthesis and Plant Genetics
New Science & Innovation Business Unit to Advance Aurora's Leadership in Biosynthesis...
About this update from Aurora Cannabis Inc.
[{"type":"text","content":"\n \n \n \n New Science & Innovation Business Unit to Advance Aurora's Leadership in Biosynthesis and Plant Genetics\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n New Science & Innovation Business Unit to Advance Aurora's Leadership in Biosynthesis and Plant Genetics\n \n \n Canada NewsWire\n \n \n \n \n \n \n The Company's patented technology expected to be key to commercial success in cannabinoid biosynthesis\n \n \n \n \n NASDAQ | TSX: ACB\n \n \n \n EDMONTON, AB\n \n ,\n \n May 27, 2021\n \n /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the launch of a dedicated Science & Innovation business group, with the aim of commercializing patented and patent pending technology that the Company believes will be key in the development of cannabinoid biosynthesis and plant genetics.\n \n \n \n \n \n \n \n \n \n Aurora's connection to the biosynthetic production of cannabinoids originated with early work carried out by the Company's former Chief Science Officer on the discovery of key genes within the cannabinoid biosynthesis pathway. Through licensing agreements, Aurora and sub-licensee 22nd Century Group together share the global IP rights to commercialize key aspects of cannabinoid biosynthesis in plants and microorganisms. The two companies are working closely to enforce their IP against infringing parties, as well as to actively explore commercial development opportunities.\n \n \n \"As global cannabis regulations evolve, we believe cannabinoid molecules, including minor cannabinoids, will be incredibly important. Today, Aurora's Reliva business in the U.S. sells products that use CBD isolate, and we are deeply interested in the evolution of other cannabinoids and the ability to commercialize them,\" says\n \n Miguel Martin\n \n , CEO of Aurora Cannabis.  \"This technology promises to be very valuable, as it potentially unlocks a more efficient means to produce cannabinoids at scale, particularly minor cannabinoids whi...